rituximab (Mabthera)

Subscribe to Selected New Research on rituximab

2613 relevant articles (575 outcomes, 446 trials/studies) found for this Drug

Description: a genetically engineered anti-CD20 antibody for the treatment of B-cell lymphoma

Also Known As:

Mabthera; Rituxan; CD20 antibody, rituximab; Genentech brand of rituximab; Hoffmann-La Roche brand of rituximab; IDEC brand of rituximab; IDEC-C2B8; IDEC-C2B8 antibody; Roche brand of rituximab

Relationship Network

Drug Context: Research Results

Amino Acids, Peptides, and Proteins

Proteins: 56522

Blood Proteins: 3890

Serum Globulins: 72

Immunoglobulins: 19903

Antibodies: 75661

Monoclonal Antibodies: 16400

rituximab: 2613

Immunoproteins: 29

Immunoglobulins: 19903

Antibodies: 75661

Monoclonal Antibodies: 16400

rituximab: 2613

Globulins: 299

Serum Globulins: 72

Immunoglobulins: 19903

Antibodies: 75661

Monoclonal Antibodies: 16400

rituximab: 2613

Experts

1.	Coiffier, Bertrand: 13 articles (07/2008 - 01/2002)
2.	Byrd, John C: 13 articles (06/2007 - 02/2002)
3.	Witzig, Thomas E: 12 articles (07/2008 - 01/2002)
4.	Baccarani, Michele: 11 articles (09/2008 - 02/2002)
5.	McLaughlin, Peter: 10 articles (09/2008 - 02/2002)
6.	Keating, Michael J: 10 articles (08/2008 - 02/2002)
7.	Engert, Andreas: 10 articles (05/2008 - 11/2002)
8.	Czuczman, Myron S: 10 articles (03/2008 - 02/2002)
9.	Habermann, Thomas M: 9 articles (10/2008 - 01/2002)
10.	Zaja, Francesco: 9 articles (09/2008 - 02/2002)

Related Diseases

1.	Non-Hodgkin Lymphoma (Lymphosarcoma) 04/01/2006 - "CHOP combined with rituximab (R-CHOP) is regarded as one of the most effective treatments for indolent B-cell non-Hodgkin lymphoma (B-NHL), however, its optimal combination schedule remains unknown" 12/01/2004 - "The anti-CD20 antibody rituximab is useful in the treatment of certain B-cell malignancies, most notably non-Hodgkin's lymphoma" 04/01/2004 - "Most experience is available for anti-CD20 (rituximab) which led to a significant improvement of the outcome in B-cell non-Hodgkin's lymphoma (NHL)" 02/01/2003 - "In summary, rituximab appears highly active as first-line single-agent therapy for indolent non-Hodgkin's lymphoma and responses may be improved with maintenance courses of rituximab" 01/01/2003 - "Although the introduction of the monoclonal antibody rituximab 5 years ago led to a marked improvement in the treatment of non-Hodgkin's lymphoma (NHL), most patients do not experience a complete response to therapy, and many who do respond relapse" Get all the results and reference details, order at left...
2.	Lymphoma (Lymphomas) 06/01/2008 - "Re: Rituximab monotherapy is highly effective in splenic marginal zone lymphoma." 09/01/2007 - "Rituximab monotherapy is highly effective in splenic marginal zone lymphoma." 08/01/2006 - "Rituximab is a chimeric anti-CD20 monoclonal antibody active against normal and malignant B cells which has proven to be effective in the therapy of CD-20 positive lymphomas" 06/01/2005 - "Therefore, rituximab was administered to the patient, resulting in complete remission of the primary gastric lymphoma" 12/01/2007 - "More importantly, rituximab-SAHA combination significantly promoted primary B-NHL cells apoptosis and improved survival time of a severe combined immunodeficient mouse lymphoma model established with intravenous injection of Daudi cells" Get all the results and reference details, order at left...
3.	B-Cell Lymphoma (Lymphoma, B Cell) 09/01/2007 - "Infusions of rituximab, a chimeric human-murine anti-CD20 antibody known to be effective in B-cell lymphoma, produced partial response rates of approximately 50% and occasional complete responses" 11/01/2006 - "We describe a woman with relapsed cutaneous follicular centre B-cell lymphoma and secondary lymph-node involvement treated with rituximab alone, which induced a complete remission" 10/01/2002 - "Sixteen other patients with cutaneous B-cell lymphomas treated with rituximab have been previously reported in the literature, with a complete remission rate of 25 p" 03/01/2002 - "Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab." 01/01/2006 - "Rituximab (anti-CD20 antibody) has been established as the gold standard of treatment for aggressive B-cell lymphomas in combination with CHOP and has shown significant activity as monotherapy in the treatment of indolent B-cell lymphomas" Get all the results and reference details, order at left...
4.	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 09/01/2006 - "Most commonly studied in patients with follicular lymphoma, the monoclonal antibody rituximab has not only improved the response rate and progression-free survival for both treatment-naive and relapsed/refractory patients, it is also beginning to demonstrate an improvement in overall survival" 03/01/2006 - "Rituximab maintenance therapy following successful induction has emerged as a highly effective treatment for follicular lymphoma" 07/01/2003 - "Results suggest that real-time PCR is superior to Genescan PCR to select transplantable harvests and confirm the ability of Rituximab as an in vivo purging tool for follicular lymphoma." 02/01/2008 - "T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy?" 06/01/2007 - "Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas." Get all the results and reference details, order at left...
5.	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell) 08/01/2005 - "Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia." 10/01/2006 - "We present the case of a 57 years old patient, with diffuse large-B cell lymphoma in complete remission, who consulted our hospital because of symmetric lower extremity weakness, developed while being treated with a rituximab maintenance schedule" 04/01/2000 - "Complete molecular remission induced by rituximab in a patient with diffuse large cell lymphoma." 05/01/2006 - "INTERPRETATION: Rituximab added to six cycles of CHOP is an effective treatment for young patients with good-prognosis diffuse large-B-cell lymphoma" 12/01/2005 - "Rituximab, an anti-CD20 monoclonal antibody, is effective in treating diffuse large B-cell lymphoma" Get all the results and reference details, order at left...
364 Diseases and 2613 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Cyclophosphamide (Cytoxan)
2.	rituximab (Mabthera)
3.	Vincristine (Oncovin)
4.	Prednisone (Sone)
5.	Doxorubicin (Adriamycin)
6.	fludarabine
7.	CD20 Antigens
8.	Methotrexate (Mexate)
9.	Mitoxantrone (Novantrone)
10.	Etoposide (VP 16)
465 Drugs and Important Bio-Agents and 1135 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Aftercare (After-Treatment)
3.	Stem Cell Transplantation
4.	Transplants (Transplant)
5.	Immunotherapy
53 Therapies and Procedures and 743 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>